DelveInsight Business Research LLP The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inadequate responses to existing therapies. New York, USA, Sept.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.